Sonnet BioTherapeutics Holdings, Inc. (SONN)
SONN Stock Price Chart
Explore Sonnet BioTherapeutics Holdings, Inc. interactive price chart. Choose custom timeframes to analyze SONN price movements and trends.
SONN Company Profile
Discover essential business fundamentals and corporate details for Sonnet BioTherapeutics Holdings, Inc. (SONN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Oct 2006
Employees
13.00
Website
https://www.sonnetbio.comCEO
Raghu Rao
Description
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
SONN Financial Timeline
Browse a chronological timeline of Sonnet BioTherapeutics Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 16 Dec 2025
Earnings released on 13 Aug 2025
EPS came in at -$0.95 falling short of the estimated -$0.49 by -93.88%.
Earnings released on 13 May 2025
EPS came in at -$0.89 surpassing the estimated -$0.92 by +3.26%.
Earnings released on 13 Feb 2025
EPS came in at -$1.56 falling short of the estimated -$1.39 by -12.23%, while revenue for the quarter reached $1.00M .
Earnings released on 19 Dec 2024
EPS came in at -$3.83 surpassing the estimated -$5.04 by +24.01%, while revenue for the quarter reached $104.39K .
Stock split effective on 30 Sept 2024
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2024
EPS came in at -$5.60 falling short of the estimated -$0.76 by -636.84%.
Earnings released on 14 May 2024
EPS came in at $0.56 surpassing the estimated $0.14 by +300.00%.
Earnings released on 14 Feb 2024
EPS came in at -$2.48 falling short of the estimated -$0.90 by -175.56%, while revenue for the quarter reached $18.63K , missing expectations by -6.87%.
Earnings released on 18 Dec 2023
EPS came in at -$2.09 surpassing the estimated -$4.09 by +48.90%, while revenue for the quarter reached $37.26K , beating expectations by +86.28%.
Stock split effective on 1 Sept 2023
Shares were split 1 : 22 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2023
EPS came in at -$22.86 falling short of the estimated -$0.31 by -7.27K%, while revenue for the quarter reached $36.85K , beating expectations by +84.25%.
Earnings released on 10 May 2023
EPS came in at -$59.78 falling short of the estimated -$0.49 by -12.10K%, while revenue for the quarter reached $36.45K .
Earnings released on 13 Feb 2023
EPS came in at -$140.66 falling short of the estimated -$1.10 by -12.69K%, while revenue for the quarter reached $37.26K , missing expectations by -62.75%.
Earnings released on 15 Dec 2022
EPS came in at -$1.67 falling short of the estimated -$1.51 by -10.60%, while revenue for the quarter reached $62.75K , missing expectations by -37.25%.
Stock split effective on 19 Sept 2022
Shares were split 1 : 14 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Aug 2022
EPS came in at -$1.82 surpassing the estimated -$1.96 by +7.14%, while revenue for the quarter reached $62.07K , beating expectations by +24.14%.
Earnings released on 10 May 2022
EPS came in at -$344.75 falling short of the estimated -$1.68 by -20.42K%, while revenue for the quarter reached $95.32K , missing expectations by -2.39%.
Earnings released on 8 Feb 2022
EPS came in at -$246.25 surpassing the estimated -$738.76 by +66.67%, while revenue for the quarter reached $129.80K , beating expectations by +199.54%.
Earnings released on 17 Dec 2021
EPS came in at -$2.45 surpassing the estimated -$3.08 by +20.45%, while revenue for the quarter reached $483.63K .
Earnings released on 16 Aug 2021
EPS came in at -$664.88 .
Earnings released on 17 May 2021
EPS came in at -$788.01 .
Earnings released on 16 Feb 2021
EPS came in at -$105.13 .
Earnings released on 17 Dec 2020
EPS came in at -$11.65K , while revenue for the quarter reached -$5.68M , missing expectations by -158.85%.
SONN Stock Performance
Access detailed SONN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.